Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, announces the divestiture of iovera ®° to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader. The iovera° system is an innovative, FDA-cleared, drug-free medical device that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Under the terms of the transaction, Pacira will receive up to $140 million with an upfront payment of $70 million and potential future revenue-based milestone payments totaling up to an additional $70 million.
Read the full article: Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet //
Source: https://www.globenewswire.com/news-release/2026/06/30/3319548/0/en/pacira-biosciences-announces-agreement-to-divest-its-iovera-business-to-zimmer-biomet.html